Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02BAA
|
|||
Drug Name |
Patient-derived CD19- and CD22 specific CAR
|
|||
Drug Type |
CAR T Cell Therapy (Dual specific)
|
|||
Indication | leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 1 | [1] | |
Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [1] | ||
Company |
Seattle Children's Hospital
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | B-cell receptor CD22 (CD22) | Target Info | CAR-T-Cell-Therapy(Dual specific) | [1] |
B-lymphocyte surface antigen B4 (CD19) | Target Info | CAR-T-Cell-Therapy(Dual specific) | [1] | |
KEGG Pathway | Cell adhesion molecules (CAMs) | |||
Hematopoietic cell lineage | ||||
B cell receptor signaling pathway | ||||
PI3K-Akt signaling pathway | ||||
Epstein-Barr virus infection | ||||
Primary immunodeficiency | ||||
NetPath Pathway | IL-7 Signaling Pathway | |||
Panther Pathway | B cell activation | |||
Pathway Interaction Database | BCR signaling pathway | |||
Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
PIP3 activates AKT signaling | ||||
Constitutive Signaling by Aberrant PI3K in Cancer | ||||
WikiPathways | B Cell Receptor Signaling Pathway | |||
Human Complement System | ||||
Signaling by the B Cell Receptor (BCR) | ||||
PIP3 activates AKT signaling | ||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.